1 results match your criteria: "Center of Neuroendocrine Tumors Bad Berka-ENETS Center of Excellence[Affiliation]"
Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry.
Recent Results Cancer Res
June 2013
Department of Gastroenterology and Endocrinology, Center of Neuroendocrine Tumors Bad Berka-ENETS Center of Excellence, Bad Berka, Germany.
Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor-expressing neuroendocrine tumors. However, published data result mainly from retrospective monocentric studies. We initiated a multi-institutional, prospective, board-reviewed registry for patients treated with peptide receptor radionuclide therapy in Germany in 2009.
View Article and Find Full Text PDF